TROPION-Lung01 Study Design and Baseline demographics
Skip in ESMO Highlight presentation
Efficacy endpoint: PFS by HER2 status per cohort
Daiichi-Sankyo
Bladder
cancer
Probability of PFS
1.0-
0.8-
0.6-
0.4-
Number at risk, month
0.2
0.0-
-3
6
-00
9
12
Median PFS in months (95% CI)
Bladder cancer: IHC 3+ 7.4 (3.0, 11.9)
Bladder cancer: IHC 2+ 7.8 (2.6, 11.6)
Bladder cancer: Total 7.0 (4.2, 9.7)
tumors
Other
Probability of PFS
1.0-
0.8-
0.6-
0.4-
0.2-
0.0-
Median PFS in months (95% CI)
Other tumors: IHC 3+ 23.4 (5.6, NR)
Other tumors: IHC 2+ 5.5 (2.8, 8.7)
Other tumors: Total 8.8 (5.5, 12.5)
T
15
18
21
24
-O
T
0
-3
6
9
12
15
18
21
24
27
Time from first dose (months)
Number at risk, month
145
0
Other tumors: IHC 3+
9
9
3
1
0
Other tumors: IHC 2+
16
9
3
1
0
Other tumors: Total
40
31
862
7
6
3
24
18
320
125
2
1
1
1
9
7
4
012
00
Time from first dose (months)
Bladder cancer: IHC 3+
Bladder cancer: IHC 2+
Bladder cancer: Total
1984
16
12
20
14
41
29
219
9
6
3
13
8
5
23
14
8
Median PFS in months (95% CI)
Pancreatic cancer: IHC 3+ 5.4 (2.8, NR)
Pancreatic cancer: IHC 2+ 2.8 (1.4, 9.1)
Pancreatic cancer: Total 3.2 (1.8, 7.2)
9
12
15
15
Time from first dose (months)
1.0-
Biliary tract
cancer
Probability of PFS
0.8-
0.6-
Median PFS in months (95% CI)
Biliary tract cancer: IHC 3+ 7.4 (2.8, 12.5)
Biliary tract cancer: IHC 2+ 4.2 (2.8, 6.0)
Biliary tract cancer: Total 4.6 (3.1, 6.0)
1.0-
0.4-
0.2-
0.0-
0
3
Pancreatic
cancer
Probability of PFS
0.8-
0.6-
0.4-
0.2-
0.01
0-
61
9
T
T
T
12
15
18
5
CO
-a
21
24
Fo
0
دلي
T
3
-6
-a
Time from first dose (months)
Number at risk, month
Number at risk, month
Biliary tract cancer: IHC 3+
16
11
9
5
5
3
2
2
0
Pancreatic cancer: IHC 3+
2
1
1
0
Biliary tract cancer: IHC 2+
14
10
3
1
1
1
1
1
0
Pancreatic cancer: IHC 2+
19
8
6
4
Biliary tract cancer: Total
41
27
14
6
6
4
3
3
0
Pancreatic cancer: Total
25
11
7
4
Circle indicates a censored observation
CI, confidence interval; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; NR, not reached; PFS, progression-free survival
22
22
0
18
22
T
21
24
00
22
49
49View entire presentation